Key Takeaways from #JPM25: Strategic Partnerships and Acquisitions Dominate the JP Morgan Healthcare Conference

Eli Lilly's Major Acquisition:
Eli Lilly acquired Scorpion Therapeutics Inc. for up to $2.5 billion, gaining rights to Scorpion’s PI3Kα inhibitor program, STX-478, for breast cancer and other advanced solid tumors3.

Zealand Pharma's Partnership Goals:
Zealand Pharma CEO Adam Steensberg expressed the company's focus on partnering with a top-10 pharma company for its amylin drug2.

GSK's Acquisition:
GSK announced the acquisition of the privately-held biotech IDRx, highlighting the active dealmaking environment at the conference1.

Industry Trends:
The conference saw discussions on the impact of Trump 2.0 on the biopharma industry, the future of M&A in 2025, and the strategic positioning of major drugmakers like Pfizer15.

Scorpion's Spinoff:
Following the acquisition, Scorpion will spin off a new independent entity to hold its non-PI3Kα pipeline assets and employees, focusing on precision medicine development3.

Sources:

1. https://endpts.com/jpm25-day-1-at-the-jp-morgan-healthcare-conference/

2. https://endpts.com/jpm25-day-3-at-the-jp-morgan-healthcare-conference/

3. https://www.geneonline.com/eli-lilly-steals-the-spotlight-at-jpm-2025-with-2-5-billion-power-move-acquisition/

5. https://endpts.com/jpm25-day-2-at-the-jp-morgan-healthcare-conference/